Abstract
The low incidence of cardiovascular disease in countries bordering the Mediterranean basin, where olive oil is the main source of dietary fat, and the negative association between this disease with high density lipoproteins has stimulated interest. This review summarizes the current knowledge gathered from human and animal studies regarding olive oil and high density lipoproteins. Cumulative evidence suggests that high density lipoprotein (HDL) cholesterol, and its main apolipoprotein A1, may be increased by consuming olive oil when compared with carbohydrate and low fat diets in humans. Conflicting results have been found in many studies when olive oil diets were compared with other sources of fat. The role of virgin olive oil minor components on its protective effect has been demonstrated by a growing number of studies although its exact mechanism remains to be elucidated. Dietary amount of olive oil, use of virgin olive oil, cholesterol intake, and physiopathological states such as genetic background, sex, age, obesity or fatty liver are variables that may offset those effects. Further studies in this field in humans and in animal models are warranted due to the complexity of HDL particles.
Keywords: Apolipoprotein, high density lipoprotein, olive oil, cardiovascular risk, obesity, coronary heart disease, hypertension, hypertriglyceridemia, metabolic syndrome
Current Vascular Pharmacology
Title:HDL-Related Mechanisms of Olive Oil Protection in Cardiovascular Disease
Volume: 10 Issue: 4
Author(s): Jose M. Lou-Bonafonte, Montse Fito, Maria-Isabel Covas, Marta Farras and Jesus Osada
Affiliation:
Keywords: Apolipoprotein, high density lipoprotein, olive oil, cardiovascular risk, obesity, coronary heart disease, hypertension, hypertriglyceridemia, metabolic syndrome
Abstract: The low incidence of cardiovascular disease in countries bordering the Mediterranean basin, where olive oil is the main source of dietary fat, and the negative association between this disease with high density lipoproteins has stimulated interest. This review summarizes the current knowledge gathered from human and animal studies regarding olive oil and high density lipoproteins. Cumulative evidence suggests that high density lipoprotein (HDL) cholesterol, and its main apolipoprotein A1, may be increased by consuming olive oil when compared with carbohydrate and low fat diets in humans. Conflicting results have been found in many studies when olive oil diets were compared with other sources of fat. The role of virgin olive oil minor components on its protective effect has been demonstrated by a growing number of studies although its exact mechanism remains to be elucidated. Dietary amount of olive oil, use of virgin olive oil, cholesterol intake, and physiopathological states such as genetic background, sex, age, obesity or fatty liver are variables that may offset those effects. Further studies in this field in humans and in animal models are warranted due to the complexity of HDL particles.
Export Options
About this article
Cite this article as:
M. Lou-Bonafonte Jose, Fito Montse, Covas Maria-Isabel, Farras Marta and Osada Jesus, HDL-Related Mechanisms of Olive Oil Protection in Cardiovascular Disease, Current Vascular Pharmacology 2012; 10 (4) . https://dx.doi.org/10.2174/157016112800812827
DOI https://dx.doi.org/10.2174/157016112800812827 |
Print ISSN 1570-1611 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-6212 |
Call for Papers in Thematic Issues
Ischemic Cardiovascular Diseases: Mechanisms, Diagnosis and Therapy
Ischemic cardiovascular disease includes myocardial infarction, coronary atherosclerotic heart disease, angina pectoris, etc., constitute the leading cause of patient mortality by preventing tissues from getting sufficient oxygen and nutrients. Ischemic heart disease, as a clinical condition, is characterized by myocardial ischemia, causing an imbalance between myocardial blood supply and demand, ...read more
TREATMENT OF CARDIOVASCULAR DISEASE IN CHRONIC AND END STAGE KIDNEY DISEASE
Cardiovascular disease still remains the leading cause of death in Chronic and End Stage Kidney Disease, accounting for more than half of all deaths in dialysis patients. During the past decade, research has been focused on novel therapeutic agents that might delay or even reverse cardiovascular disease and vascular calcification, ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Does Pregnancy Affect the Metabolic Equivalent at Rest and During Low Intensity Exercise?
Current Women`s Health Reviews Are Selenoproteins Important for the Cancer Protective Effects of Selenium?
Current Nutrition & Food Science Analysis of Functional Brain Images Using Population-Based Probabilistic Atlas
Current Medical Imaging Pigment Epithelium-derived Factor (PEDF) and Cardiometabolic Disorders
Current Pharmaceutical Design Bevacizumab and Angiogenesis Inhibitors in the Treatment of CNS Metastases: The Road less Travelled
Current Molecular Pharmacology Phytocannabinoids and Cannabimimetic Drugs: Recent Patents in Central Nervous System Disorders
Recent Patents on CNS Drug Discovery (Discontinued) Ticagrelor: A Novel Drug for an Old Problem
Recent Patents on Cardiovascular Drug Discovery Pulmonary Hypertension in the Critically Ill
Current Hypertension Reviews Microvascular Thrombosis: An Exciting but Elusive Therapeutic Target in Reperfused Acute Myocardial Infarction
Cardiovascular & Hematological Disorders-Drug Targets Cilostazol in the Management of Atherosclerosis
Current Vascular Pharmacology The Emerging Role of Complement C3 as A Biomarker of Insulin Resistance and Cardiometabolic Diseases: Preclinical and Clinical Evidence
Reviews on Recent Clinical Trials The Association Between Keratoconus and Mitral Valve Prolapse: A Meta-Analysis
Current Cardiology Reviews Killing Glioma ‘Stem-like’ Cells via Drug-Induced Relocation of Endosomal Urokinase Proteins
Anti-Cancer Agents in Medicinal Chemistry Small Molecule Inhibitors of Peptidylprolyl cis/trans Isomerase
Current Enzyme Inhibition Molecular and Cellular Pathways as a Target of Therapeutic Hypothermia: Pharmacological Aspect
Current Neuropharmacology Meet Our Editorial Board Member
Recent Patents on CNS Drug Discovery (Discontinued) Dyslipidemia as a Risk Factor for Erectile Dysfunction
Current Medicinal Chemistry New Insights on the Impact of Statin Therapy in the Susceptibility to Hypovitaminosis D Through Serum Lipidome Profiling
Cardiovascular & Hematological Agents in Medicinal Chemistry Sorafenib (BAY 43-9006): Review of Clinical Development
Current Clinical Pharmacology Editorial: Can Glucagon Like Peptide 1 (GLP1) Agonists or Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors Ameliorate Non-Alcoholic Steatohepatitis in People with or without Diabetes?
Current Vascular Pharmacology